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Objective: Haematopoietic stem cell transplantation (HSCT) is
frequently complicated by early Human herpesvirus type 6
(HHV6) reactivation and is associated with poor survival and severe
acute Graft-versus-host-disease (aGvHD). We hypothesized that
HHV6may be a trigger for immunedysregulation, resulting in allor-
eactivity. We investigated total T-cell numbers and HHV6-specific
Interferon-g (IFNg) producing T-cells in children with or without
HHV6-reactivation after HSCT using a newly developed enzyme-
linked immunospot (ELISPOT) technique.
Methods: Prospectively, HHV6, Cytomegalovirus, Adenovirus
and Epstein Barr virus DNA-loads were weekly monitored by quan-
titative realtime-PCR and clinical data were collected. HHV6 reac-
tivation was defined as HHV6 DNA-load .250cp/mL. T-cell
reconstitution was prospectively measured every other week by im-
munophenotyping (markers CD3, CD4 and CD8). Numbers of
IFNg-producingT-cells in PBMCswere retrospectively determined
by ELISPOT after overnight stimulation with HHV6-virus lysate
(ABI, Columbia, Maryland, USA) 2 months after HSCT.
Results: Twenty-one HSCT patients were analyzed (median age
4.4 years; range 1–16.5yrs). Within the first two months, 13/21
(62%) patients developed HHV6 reactivation; median time of reacti-
vation was 14 (range 1–41) days. The development of other virusreac-
tivations did not differ between the two groups; 4/13 versus 3/8
respectively. The median number of IFNg-producing specific
HHV6 T-cells 2 months after HSCT was significantly increased in
the patients with HHV6-reactivation; 40 (0–362) versus 0 (0–25) spe-
cificT-cells permillionPBMCs (p5 0.006). Additionally, themedian
CD31 T-cell numbers were significantly increased in these patients;
393 (32–5514) versus 93 (0–641) T-cells/uL (p5 0.03), includingme-
dian CD81 T-cells; 79% (6–87 %) versus 33% (0–83%) (p5 0.03).
Conclusions: Patients with HHV6 reactivation had significantly
higher numbers of IFNg-producing HHV6-specific T-cells and
more CD31T-cells/uL, among which mainly CD81T-cells. Given
the association of HHV6 reactivation and aGvHD, these T-cells
may be alloreactive.393
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Background: Haematopoietic stem cell transplantation (HSCT)
is frequently complicated by human herpesvirus 6 (HHV6), cyto-
megalovirus (CMV) or Epstein Barr virus (EBV) reactivations. Her-
pesvirusreactivations are associated with severe morbidity and
mortality after HSCT. Although T-lymphocytes play an important
role in the clearance of viral reactivations after HSCT, an easy mea-
sure of potent T-cell responses for predicting outcome of viral reac-
tivations is lacking. We analyzed expression of perforin (a cytolytic
pore-forming protein) as a marker for cytotoxic potential in
CD81T-cells in children and related this to the clearance of viral re-
activations after HSCT.
Methods: In a prospective cohortstudy (2007–2008), we weekly
monitored HHV6, CMV and EBV DNA loads in plasma after
HSCT by quantitative realtime PCR. Herpesvirus reactivation was
defined as DNA load .1000 cp/mL. CMV- and EBVreactivation
were treated according to local guidelines. HHV6reactivation was
treated when there was clinical suspicion of disease. We have weekly
analyzed Perforin expression in CD81T-cells by whole blood FAC-
Sanalysis, until 4 months after HSCT.
Results: A total of 27 patients were included with a median age of
4.3 (range 0.3–20.1) years. 15/27 (56%) recipients received bone-
marrow (7/15 from matched family donors) or unrelated peripheral
blood stemcells while 12/27 (44%) recipients received unrelated
cordblood stemcells. All patients received myeloablative condition-
ing and standardized Graft-versus-host disease prophylaxis. During
the first 4 months after HSCT, 16 patients developed HHV6reacti-
vation, 2 patients developed CMVreactivation and 1 patient devel-oped EBVreactivation. The median time of herpesvirusreactivation
peak was 2.4 weeks (range 1.3–15.6) after HSCT. Viral clearance
was marked by a perforin peak in CD81 T-cells; median time of
maximum perforin expression in CD81T-cells was 4 weeks (range
1.4–15.9) after HSCT. Patients with herpesvirusreactivation
(HHV6, CMVorEBV) showed significantly higher perforin-expres-
sion in CD81T-cells during viral load clearance than patients with-
out herpesvirusreactivation (17.2% (range 0–63%) versus 6.8%
(range 0–16%); p 5 0.003).
Conclusion: Herpesvirus reactivation clearance was significantly
associated with a peak in perforin-expressing CD81T-cells. Al-
though virus-specific immune responses after HSCT have to be elu-
cidated, perforin expression in T-cells is a useful marker for antiviral
T-cell responses and viral load clearance after HSCT.
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ENHANCED IN VITRO EXPRESSION OF NKG2D LIGANDSMIC A ANDMIC B
WITH HISTONE DEACETYLASE INHIBITOR (HDACI) ROMIDEPSIN IN PE-
DIATRIC LEUKEMIA AND LYMPHOMAS: POTENTIAL FOR NATURAL
KILLER CELL MEDIATED TARGETED ADOPTIVE CELLULAR IMMUNO-
THERAPY (ACI)
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NK cells play a significant role in tumor cell recognition and cyto-
toxicity (Trinchieri et al Adv Immunol, 1990). NKG2D-mediated
recognition of malignant cells by NK cells is enabled through the tu-
mor-associated expression of NKG2DL. Among these NKG2DL,
MIC A and B are significantly expressed on epithelial compared to
hematological tumors (Bauer et al Science, 1999). Skov et al (Cancer
Res, 2005) demonstrated a significant increase in surface expression
of MIC A and B in various epithelial cancer cell lines after exposure
toHDACi.We compared the expression of NKG2DLMICA and B
in common pediatric hematological tumor cell lines and the impact
of enhanced expression of NKG2DL on NK cell mediated cytotox-
icity. Cell lines used were: ALL (SUP-B15, RS 4:11, REH, Jurkat),
NHL (Toledo, Ramos). Cells were co-cultured for 24hrs with 0, 5
and 10ng/ml of Romidepsin. MICA/B PE antibody was used for
flow cytometry staining. Purified adult peripheral blood NK
(CD561/3-) cells and IL-2 activated NK cells (12hr incubation)
were added to target cells (cultured with 5–10ng/ml of Romidepsin
x 24hrs) at effector to target ratio of 5:1 and 10:1 and incubated
for 2hrs. NK cell cytotoxicity was determined by a standard euro-
pium assay. There was a significant increase in expression of
MICA/B in ALL cell lines when co-cultured with Romidepsin at
10ng/ml (RS 4:11 0.2% vs 19.2% p\0.0001, REH 0.2% vs 46%
p 5 0.0003, Jurkat 1.12% vs 44.7% p\0.0001). We also noted sig-
nificant increase in MICA/B in some NHL cell lines when co-
cultured with Romidepsin at 10ng/ml (Toledo [DLBCL] 0.5% vs
15.8% p5 0.0001, Ramos [BL] 0.57% vs 33.6% p5 0.0003). There
was significant increase in vitro cytotoxicty in RS 4:11 cells at E:T
ratio of 5:1 and 10:1 (5:1 specific release: RS 4:11 cells1NK cells
vs. RS 4:11 cells1IL-2 activatedNK cells vs. RS 4:11 cells1NK cells
with 10ng/ml of Romidepsin vs. RS 4:11 cells1IL-2 activated NK
cells with 10ng/ml of Romidepsin was 3.3% vs 6% vs 45% vs
61.6% p\0.01, and at 10:1 ratio 9.3% vs 10.6% vs 71.6% vs
86.3% p\0.05, respectively). In summary, these results suggest
that Romidepsin induces significant expression of MICA/B ligands,
enhancing their susceptibility for NKG2D-mediated cytotoxicity by
NK cells. The combination of Romidepsin and NK cells presents
a potential for ACI. Future studies will be conducted with MIC A
and B antibodies to determine the specificity of the Romidepsin ef-
fect and the invivo cytotoxicity in a human/mouse xenograft SCID
model.395
ABSOLUTE LYMPHOCYTE COUNT AT DAY 30 PREDICTS SURVIVAL IN RE-
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CELL TRANSPLANTATION
Goldberg, J.D.1, Lai, K.C.1, Jakubowski, A.A.1, Barker, J.N.1,
Boulad, F.2, Castro-Malaspina, H.R.1, Hsu, K.C.1, Kernan, N.2,
142 Poster Session-IIO’Reilly, R.J.2, Papadopoulos, E.B.1, Prockop, S.2, Scaradavou, A.2,
Small, T.N.2, van den Brink, M.R.M.1, Young, J.W.1, Heller, G.3,
Perales, M.-A.1 1Memorial Sloan-Kettering Cancer Center, New York,
NY; 2Memorial Sloan-Kettering Cancer Center, New York, NY; 3Memo-
rial Sloan-Kettering Cancer Center, New York, NY
Background: Immune recovery is an important determinant of
outcome after allogeneic hematopoietic stem cell transplantation (al-
loHSCT).While T cell depleted (TCD) alloHSCT has a low risk of
graft-versus-host disease (GVHD), older adult recipients of a TCD
alloHSCTexperience deficiencies in their B andTcell reconstitution
that can persist for more than one year. We have previously shown
that the rate of recovery ofCD41Tcells followingTCD-alloHSCT
correlates with the risk of developing opportunistic infections. How-
ever, it is not known if there are any earlier immunologic predictors of
clinical outcome in the fully TCD setting.
Methods:We conducted a retrospective study of 85 consecutive
patients (median age 36, range 4–63) who received an TCD-al-
loHSCT for primary AML between January 1997 and December
2005 at MSKCC. Patients were in hematologic CR and were alive
with stable engraftment at 30 days. Immune recovery data for the
first 90 days, including absolute lymphocyte count and lymphocyte
subsets, was grouped by tertile of cohort. We also evaluated other
factors including sex of patient/donor, stage, cytogenetic risk, stem
cell source, preparative regimen, and HLA match. Kaplan-Meier
method was used to estimate overall survival (OS) and disease
free survival (DFS). The log rank test for discrete covariates and
the Cox regression model for continuous covariates were used to
determine the significance of differences in survival between
groups.
Results: Absolute lymphocyte count at day 30 (ALC30) was sig-
nificantly associated with improved OS (p 5 0.022) and a trend to-
wards improved DFS (p 5 0.082). The tertile cohorts for ALC30
were\ 0.3, 0.3–0.628, .0.628  103/mcl. Lymphocyte subsets, in-
cluding CD41, CD81, and NK cells, were not associated with OS
or DFS in the first 90 days, although the analysis may have been in-
sufficiently powered because data were not available for all patients.
Degree of HLAmatch was the only other factor predictive of OS and
DFS (p 5 0.018, 0.01).
Conclusions:WeconcludeALC30 is an early predictor ofOS and
DFS in the fully TCD setting. These results are in agreement with
earlier work demonstrating ALC30 predicts OS and relapse rate in
conventional and partially TCD transplants. Because our group is
currently investigating agents like IL-7 andKGF to improve immune
reconstitution followingTCD-alloHSCT, these results offer power-
ful guidance forwhich patientsmay benefitmost from these interven-
tions.396
IMPAIRED ANTI-VIRAL IMMUNITY FOLLOWING SYNGENEIC BONE MAR-
ROW TRANSPLANT
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Patients receiving autologous hematopoietic stem cell transplan-
tation (HSCT) or bone marrow transplantation (BMT) as therapy
for various malignancies or autoimmune diseases have an increased
risk for infectious complications post-transplant, especially in the
lung.We have used syngeneic BMT inmice and the murine gamma-
herpesvirus, MHV-68, to study the efficacy of adaptive immune re-
sponses post-HSCT. Using this model, we have shown that mice 5
weeks post-transplant have fully reconstituted their hematopoeitic
lineages in both the lung and periphery. However, the BMT mice
have a reduced ability to clear lytic virus from the lung, despite in-
creased expression of interferon gamma, interleukin-2, and TNF-al-
pha in the lungs of BMT mice. Recruitment of immune cells to the
lungs after MHV-68 infection is similar in BMT mice and untrans-
planted controls, suggesting functional defects.While bone-marrow
derived dendritic cells from transplanted mice are able to stimulate
allogeneic T cell proliferation in mixed leukocyte reactions
(MLRs), CD41 T cells from BMTmice show reduced proliferative
responses in MLRs. These results suggest defects in CD41 T cell
responses post-BMT may contribute to enhanced susceptibility to
viral infections. Studies to elucidate the mechanisms of these defects
are currently underway.TRANSPLANT NURSING-ADMINISTRATION397
EXPLORING CULTURAL DIVERSITY
Cfarku, M. Stanford Hospital and Clinics, Stanford, CA
Goals: To promote cultural awareness and improve our under-
standing of the cultural diversityof our teammembers andour patients.
Background: At our large teaching hospital in Northern Califor-
nia, there are approximately 100 team members providing care for
transplant recipients and families. On our interdisciplinary team
we have 15 different cultures represented, which is also a reflection
of our patient population. We have team members from Ethiopia,
Kenya, The Phillipines, India, Fiji, Mexico, Cuba, Canada, Albania,
Iran, Russia, Vietnam, China, Belgium, and Portugal.
Project: Once a month a staff member is chosen for a Cultural
Question and Answer (Q&A) session and potluck. The staff member
presents information on his/her culture including topics such as his-
tory, government, education, cuisine, and the health care system. For
the potluck, everybody brings a dish representative of the culture. In
addition to asking about the country and culture, the moderator also
asks about the experiences of the staff member as an immigrant to the
United States such as: Why did you immigrate? How long have you
been in this country?What was the hardest custom to adapt or cope
with since you arrived in the United States?
Results: At our first potluck, over 16members of the interdisciplin-
ary teamattended tohear about the culture ofEthopia.The enthusiasm
was evident as virtually all who attended actively participated. At the
end of the Q&A, the staff discussed how to apply what we learned to
our daily practice in caring for patients of that particular cultural back-
ground. A second benefit is that it helps to build a more cohesive team
based on an improved cultural understanding of each other. The Cul-
tural Q&A is proving to be a fun and easy way to promote cultural
awareness and improve our understanding of different cultures.398
HOWUABHOSPITAL’S BMT UNIT USED COLLABORATIVE PARTNERSHIPS
TO ANSWER THE CALL OF AN INCREASED NEED FOR HOUSE ICU BEDS
WHILE ADDRESSING ISSUES OF A FLUCTUATING BMT SPECIALTY
CENSUS
Madden, W. University of Alabama at Birmingham Hospital, Birming-
ham, AL
University of Alabama at Birmingham Hospital’s Bone Marrow
Transplantation and Cell Therapy Unit (BMT) is a unique unit that
takes pride in having certified nurses who excel in their field. Putting
patients and their safety first is the key element in our unit’s culture.
Through interdisciplinary collaboration, we restructured our unit to
address the needs of the BMT service and the issues following BMT
census fluctuation. This census fluctuation resulted in an increase in
non BMT patients including post surgical, orthopedic, hospitalist,
and many other varying patient types increasing infection risks to
our vulnerable patient populations and decreasing staff satisfaction.
Unit leaders recognized the need for the organization to increase the
number of ICU beds and the unit’s need to build a partnership with
another specialty. We collectively made a decision to become the des-
ignated overflowunit forMICUpatients during drops inBMTcensus.
While the partnership with MICU could not be monogamous, open-
ing the doors toMICU alsomeant opening to all ICU services in need
and therefore officially claiming BMT as a needed addition to the in-
tensive care units at UAB Hospital. Education of the staff remains an
ever changing process improvement on our unit. Culture initiatives to
keep morale high during change continue to be a focus point for unit
leaders. The partnership has proven to be both challenging and re-
warding. The benefits and success stories of the patients we have
helped far outweigh the challenges and grief. Our focus supports our
unit motto. Always About Them, Never About Us.399
BUILDING A FOUNDATION TO EXCEL AT CONDUCTING CLINICAL AND
TRANSLATIONAL RESEARCH
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